APO RESEARCH · REPORT
Gastrointestinal
Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders.
Product & engineering
Understand the product.
Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders.
Selected research
Industry Research
Gastrointestinal Industry Research Report 2026
Market perspective
Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders.
Global Gastrointestinal key players include AstraZeneca, Sanofi, Bayer, Pfizer, GlaxoSmithKline, etc. Global top five manufacturers hold a share over 25%.
Europe is the largest market, with a share about 45%, followed by Asia, and North America, both have a share over 45 percent.
Read the full market overview
In terms of product, Prescription Gastrointestinal Drug is the largest segment, with a share over 80%. And in terms of application, the largest application is Chronic Gastritis, followed by Peptic Ulcer, etc.
Report Scope
This report quantifies the global Gastrointestinal market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Gastrointestinal.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Gastrointestinal Market by Company
AstraZenec
Sanofi
Bayer
Pfizer
GlaxoSmithKline
Teva
Zeria（Tillotts）
Perrigo
Boehringer Ingelheim
Purdue Pharma
C.B. Fleet
Abbott
Jiangzhong
Xian-Janssen
Gastrointestinal Segment by Type
Prescription Gastrointestinal Drug
OTC Gastrointestinal Drug
Gastrointestinal Segment by Application
Chronic Gastritis
Functional Dyspepsia
Peptic Ulcer
Acute Gastroenteritis
Others
Gastrointestinal Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastrointestinal market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastrointestinal and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastrointestinal.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Gastrointestinal companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Prescription Gastrointestinal Drug
- OTC Gastrointestinal Drug
Applications
- Chronic Gastritis
- Functional Dyspepsia
- Peptic Ulcer
- Acute Gastroenteritis
- Others
Companies covered
- AstraZenec
- Sanofi
- Bayer
- Pfizer
- GlaxoSmithKline
- Teva
- Zeria（Tillotts）
- Perrigo
- Boehringer Ingelheim
- Purdue Pharma
- C.B. Fleet
- Abbott
- Jiangzhong
- Xian-Janssen
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Gastrointestinal by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Prescription Gastrointestinal Drug
- 2.2.3 OTC Gastrointestinal Drug
- 2.3 Gastrointestinal by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Chronic Gastritis
- 2.3.3 Functional Dyspepsia
- 2.3.4 Peptic Ulcer
- 2.3.5 Acute Gastroenteritis
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Gastrointestinal Breakdown Data by Type
- 3.1 Global Gastrointestinal Historic Market Size by Type (2021-2026)
- 3.2 Global Gastrointestinal Forecasted Market Size by Type (2027-2032)
4 Gastrointestinal Breakdown Data by Application
- 4.1 Global Gastrointestinal Historic Market Size by Application (2021-2026)
- 4.2 Global Gastrointestinal Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Gastrointestinal Market Perspective (2021-2032)
- 5.2 Global Gastrointestinal Growth Trends by Region
- 5.2.1 Global Gastrointestinal Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Gastrointestinal Historic Market Size by Region (2021-2026)
- 5.2.3 Gastrointestinal Forecasted Market Size by Region (2027-2032)
- 5.3 Gastrointestinal Market Dynamics
- 5.3.1 Gastrointestinal Industry Trends
- 5.3.2 Gastrointestinal Market Drivers
- 5.3.3 Gastrointestinal Market Challenges
- 5.3.4 Gastrointestinal Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Gastrointestinal Players by Revenue
- 6.1.1 Global Top Gastrointestinal Players by Revenue (2021-2026)
- 6.1.2 Global Gastrointestinal Revenue Market Share by Players (2021-2026)
- 6.2 Global Gastrointestinal Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Gastrointestinal Head Office and Area Served
- 6.4 Global Gastrointestinal Players, Product Type & Application
- 6.5 Global Gastrointestinal Manufacturers Established Date
- 6.6 Global Gastrointestinal Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Gastrointestinal Market Size (2021-2032)
- 7.2 North America Gastrointestinal Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Gastrointestinal Market Size by Country (2021-2026)
- 7.4 North America Gastrointestinal Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Gastrointestinal Market Size (2021-2032)
- 8.2 Europe Gastrointestinal Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Gastrointestinal Market Size by Country (2021-2026)
- 8.4 Europe Gastrointestinal Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Gastrointestinal Market Size (2021-2032)
- 9.2 Asia-Pacific Gastrointestinal Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Gastrointestinal Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Gastrointestinal Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Gastrointestinal Market Size (2021-2032)
- 10.2 South America Gastrointestinal Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Gastrointestinal Market Size by Country (2021-2026)
- 10.4 South America Gastrointestinal Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Gastrointestinal Market Size (2021-2032)
- 11.2 Middle East & Africa Gastrointestinal Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Gastrointestinal Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Gastrointestinal Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 AstraZenec
- 12.1.1 AstraZenec Company Information
- 12.1.2 AstraZenec Business Overview
- 12.1.3 AstraZenec Revenue in Gastrointestinal Business (2021-2026)
- 12.1.4 AstraZenec Gastrointestinal Product Portfolio
- 12.1.5 AstraZenec Recent Developments
- 12.2 Sanofi
- 12.2.1 Sanofi Company Information
- 12.2.2 Sanofi Business Overview
- 12.2.3 Sanofi Revenue in Gastrointestinal Business (2021-2026)
- 12.2.4 Sanofi Gastrointestinal Product Portfolio
- 12.2.5 Sanofi Recent Developments
- 12.3 Bayer
- 12.3.1 Bayer Company Information
- 12.3.2 Bayer Business Overview
- 12.3.3 Bayer Revenue in Gastrointestinal Business (2021-2026)
- 12.3.4 Bayer Gastrointestinal Product Portfolio
- 12.3.5 Bayer Recent Developments
- 12.4 Pfizer
- 12.4.1 Pfizer Company Information
- 12.4.2 Pfizer Business Overview
- 12.4.3 Pfizer Revenue in Gastrointestinal Business (2021-2026)
- 12.4.4 Pfizer Gastrointestinal Product Portfolio
- 12.4.5 Pfizer Recent Developments
- 12.5 GlaxoSmithKline
- 12.5.1 GlaxoSmithKline Company Information
- 12.5.2 GlaxoSmithKline Business Overview
- 12.5.3 GlaxoSmithKline Revenue in Gastrointestinal Business (2021-2026)
- 12.5.4 GlaxoSmithKline Gastrointestinal Product Portfolio
- 12.5.5 GlaxoSmithKline Recent Developments
- 12.6 Teva
- 12.6.1 Teva Company Information
- 12.6.2 Teva Business Overview
- 12.6.3 Teva Revenue in Gastrointestinal Business (2021-2026)
- 12.6.4 Teva Gastrointestinal Product Portfolio
- 12.6.5 Teva Recent Developments
- 12.7 Zeria（Tillotts）
- 12.7.1 Zeria（Tillotts） Company Information
- 12.7.2 Zeria（Tillotts） Business Overview
- 12.7.3 Zeria（Tillotts） Revenue in Gastrointestinal Business (2021-2026)
- 12.7.4 Zeria（Tillotts） Gastrointestinal Product Portfolio
- 12.7.5 Zeria（Tillotts） Recent Developments
- 12.8 Perrigo
- 12.8.1 Perrigo Company Information
- 12.8.2 Perrigo Business Overview
- 12.8.3 Perrigo Revenue in Gastrointestinal Business (2021-2026)
- 12.8.4 Perrigo Gastrointestinal Product Portfolio
- 12.8.5 Perrigo Recent Developments
- 12.9 Boehringer Ingelheim
- 12.9.1 Boehringer Ingelheim Company Information
- 12.9.2 Boehringer Ingelheim Business Overview
- 12.9.3 Boehringer Ingelheim Revenue in Gastrointestinal Business (2021-2026)
- 12.9.4 Boehringer Ingelheim Gastrointestinal Product Portfolio
- 12.9.5 Boehringer Ingelheim Recent Developments
- 12.10 Purdue Pharma
- 12.10.1 Purdue Pharma Company Information
- 12.10.2 Purdue Pharma Business Overview
- 12.10.3 Purdue Pharma Revenue in Gastrointestinal Business (2021-2026)
- 12.10.4 Purdue Pharma Gastrointestinal Product Portfolio
- 12.10.5 Purdue Pharma Recent Developments
- 12.11 C.B. Fleet
- 12.11.1 C.B. Fleet Company Information
- 12.11.2 C.B. Fleet Business Overview
- 12.11.3 C.B. Fleet Revenue in Gastrointestinal Business (2021-2026)
- 12.11.4 C.B. Fleet Gastrointestinal Product Portfolio
- 12.11.5 C.B. Fleet Recent Developments
- 12.12 Abbott
- 12.12.1 Abbott Company Information
- 12.12.2 Abbott Business Overview
- 12.12.3 Abbott Revenue in Gastrointestinal Business (2021-2026)
- 12.12.4 Abbott Gastrointestinal Product Portfolio
- 12.12.5 Abbott Recent Developments
- 12.13 Jiangzhong
- 12.13.1 Jiangzhong Company Information
- 12.13.2 Jiangzhong Business Overview
- 12.13.3 Jiangzhong Revenue in Gastrointestinal Business (2021-2026)
- 12.13.4 Jiangzhong Gastrointestinal Product Portfolio
- 12.13.5 Jiangzhong Recent Developments
- 12.14 Xian-Janssen
- 12.14.1 Xian-Janssen Company Information
- 12.14.2 Xian-Janssen Business Overview
- 12.14.3 Xian-Janssen Revenue in Gastrointestinal Business (2021-2026)
- 12.14.4 Xian-Janssen Gastrointestinal Product Portfolio
- 12.14.5 Xian-Janssen Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst